Navigation Links
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Date:2/7/2013

platform.  This technology enhances delivery of key target proteins like HER2 for cancer to a critical immune recognition site enhancing immune recognition. The Company has also developed compounds designed for important non-HER2 cancer associated protein targets using the Ii-Key technology platform. These include the melanoma-associated gp100 target, as well as cervical and head-and-neck cancers associated with Human Papilloma Virus (HPV). These compounds have shown significant activity in animal models that has been described in peer-reviewed publications.

In addition to cancer protein targets, the Company has clinically tested Ii-Key-based proteins designed to protect against the potentially pandemic influenza strains H5N1 (avian flu) and H1N1 (swine flu). The advantage here is that the Antigen vaccine technology is entirely synthetic, making it simple to manufacture. In the event of a potentially pandemic influenza virus, there is clearly a need for this type of flexible vaccine technology that can be brought into production rapidly.

The distinguishing feature of Antigen Express technology (Ii-Key) is the ability to activate critical components of the immune system (CD4+ T helper cells) in a robust and specific manner. Currently this is a unique technology platform that directs proteins to a critical immune component to be able to create specific immune stimulation. This Ii-Key technology is proprietary to Antigen Express. Consequently, the Company is in a good position to license the technology for combination with multiple different target proteins to create novel vaccine applications that may be of interest to other researchers and companies.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavit
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015  Today, the National Mobility Equipment ... 2015 National Mobility Awareness Month Local Heroes Contest on ... online entries that received 1.3 million votes. The sponsors ... Toyota Mobility , and Valley Honda Dealers ... and Vantage Mobility International (VMI) and ...
(Date:6/30/2015)... Calif. , June 30, 2015  Avanir ... PRISM II study showing that treatment with NUEDEXTA ... reduction in symptoms of pseudobulbar affect (PBA) in ... PBA is a distressing condition characterized by sudden ... from certain neurologic diseases or brain injury. PRISM ...
(Date:6/30/2015)... Minn. , June 30, 2015  EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering  of 40,229,886 units. Each ... of a Series A warrant to purchase one share ... warrant to purchase one share of common stock, at ...
Breaking Medicine Technology:NMEDA Announces National Contest Winners 2NMEDA Announces National Contest Winners 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3
(Date:6/30/2015)... ... 2015 , ... Lecrae is quickly developing into one of the biggest music ... New York Times to Billboard Magazine and Variety, among others. His transparency and ... why so many people are taking notice. , “We are very excited about this ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... be held October 28-31, 2015 at Disney’s Coronado Springs Resort in Lake Buena ... and networking. Each year, this premiere event for psychiatric-mental health nursing draws more ...
(Date:6/30/2015)... ... 2015 , ... Izenda is proud to acknowledge the hard ... an accredited American educational institution through its scholarship program. , In today's Age ... environment, political campaigns, and a variety of other worldwide trends. Modern day technology ...
(Date:6/30/2015)... ... June 30, 2015 , ... Americans report feeling more ... buzzer on Monday mornings, which puts stressed out people right over the edge. ... 22% suffering from sleep deprivation every night. Sleeping pills now lead the list of ...
(Date:6/30/2015)... ... June 30, 2015 , ... Scott Purdy, the spokesperson for ... Provider XO. Scott Purdy stated that the XO stands for eXtra Operability (XO) which ... the workflow processes of the Revenue Cycle. , Provider XO, based in Cleveland ...
Breaking Medicine News(10 mins):Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 2Health News:Hands of Hope to Present Grammy Award-Winner Lecrae in Concert this August 3Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 2Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 3Health News:Izenda Offers Embedded BI and Analytics Scholarship 2Health News:Izenda Offers Embedded BI and Analytics Scholarship 3Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 2Health News:Wake UP Happy and Sleep Soundly with Famous Experts with My Wake UP Call® Motivational Alarm Clock® Messages and My Good Night Messages™ - Now Available at Audible! 3Health News:Dephinitive Systems Is Getting a New Name 2
... a third of American,adults take some type of multivitamin ... is better health, even though there is no firm ... one thing, but the presence of,harm is another: A ... concluded that there was an increased prostate cancer risk ...
... to Stethoscope, the distinguished public lecture series organized by ... (MUHC), is embarking on a second season. "Again this ... on a journey into a possible future, when current ... declared Dr. Arthur T. Porter, Director General of the ...
... The Russell,Investment Group has advised Protalix Biotherapeutics ... float weight adjustment effective after the close of,trading ... Russell 2000,Russell 2000 Growth, Russell 2500, Russell 2500 ... Growth, Russell Small Cap,Completeness and the Russell Small ...
... Sept. 28 Transcept,Pharmaceuticals, Inc., a specialty pharmaceutical ... drugs, today announced,that Glenn A. Oclassen, President and ... 2007 BIO Investor Forum at the Palace Hotel ... 3:00 PM Pacific Time. About Transcept Pharmaceuticals ...
... Doctors need to be more proactive in diagnosing the condition, ... in seven women suffers from depression before, during or after ... can be devastating to the mother, her baby and her ... of The American Journal of Psychiatry . , ...
... M. Williams Speak Out on Mental Health Crisis,Facing ... Experts in mental,health, Members of Congress and other ... Caucus Foundation,s 2007 Annual,Legislative Conference to shed light ... Needs." Rep. Julia Carson (D - IN) together,with ...
Cached Medicine News:Health News:Excessive Multivitamin Use May Raise Risk for Prostate Cancer, from Harvard Men's Health Watch 2Health News:Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment 2Health News:15% of Women Struggle With Pregnancy-Related Depression 2Health News:15% of Women Struggle With Pregnancy-Related Depression 3Health News:Black America Urged to Confront Its Secret Pain: Depression 2Health News:Black America Urged to Confront Its Secret Pain: Depression 3Health News:Black America Urged to Confront Its Secret Pain: Depression 4Health News:Black America Urged to Confront Its Secret Pain: Depression 5